Allergy Therapeutics PLC - biotechnology firm - Following discussions from Paul Ehrlich Institute, analysis of primary endpoint data of the Birch MATA MPL pivotal phase III clinical trial has been declared invalid, due to technical issues in study making it impossible to reconstruct endpoint data. As a result, new phase III study will be conducted within the therapy allergens ordinance.
Current stock price: 14.00 pence
Year-to-date change: 37%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Allergy Thera. (AGY)